Stevanato Group SpA (STVN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Stevanato Group SpA stock (STVN) is currently trading at $14.18. Stevanato Group SpA PE ratio is 24.31. Stevanato Group SpA PS ratio (Price-to-Sales) is 3.30. Analyst consensus price target for STVN is $25.46. WallStSmart rates STVN as Underperform.
- STVN PE ratio analysis and historical PE chart
- STVN PS ratio (Price-to-Sales) history and trend
- STVN intrinsic value — DCF, Graham Number, EPV models
- STVN stock price prediction 2025 2026 2027 2028 2029 2030
- STVN fair value vs current price
- STVN insider transactions and insider buying
- Is STVN undervalued or overvalued?
- Stevanato Group SpA financial analysis — revenue, earnings, cash flow
- STVN Piotroski F-Score and Altman Z-Score
- STVN analyst price target and Smart Rating
Stevanato Group SpA
📊 No data available
Try selecting a different time range
STVN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Stevanato Group SpA (STVN)
STVN trades 263% above its Graham fair value of $4.30, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Stevanato Group SpA (STVN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, institutional own.. Concerns around peg ratio and return on equity. Fundamentals are solid but monitor weak areas for improvement.
Stevanato Group SpA (STVN) Key Strengths (3)
108.93% of shares held by major funds and institutions
Strong operational efficiency: $21 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Stevanato Group SpA (STVN) Areas to Watch (7)
Very expensive relative to growth, significant premium
Revenue growing slowly at 4.80% annually
Earnings barely growing at 0.30%
Low profitability relative to shareholder equity
Revenue is fairly priced at 3.30x sales
Fairly priced relative to book value
Decent profitability, keeps $12 per $100 revenue
Stevanato Group SpA (STVN) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 3.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Operating Margin, Market Cap. Profitability is solid with Operating Margin at 20.90%.
The Bear Case
The primary concerns are PEG Ratio, Revenue Growth, EPS Growth. Some valuation metrics including PEG Ratio (3.57), Price/Sales (3.30), Price/Book (2.34) suggest expensive pricing. Growth concerns include Revenue Growth at 4.80%, EPS Growth at 0.30%, which may limit upside. Profitability pressure is visible in Return on Equity at 9.67%, Profit Margin at 11.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 9.67% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Operating Margin) and negatives (PEG Ratio, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STVN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STVN's Price-to-Sales ratio of 3.30x trades 131% above its historical average of 1.43x (89th percentile), historically expensive. The current valuation is 10% below its historical high of 3.66x set in Mar 2026, and 371% above its historical low of 0.7x in Feb 2026. Over the past 12 months, the PS ratio has expanded from ~0.9x, reflecting growing market expectations outpacing revenue growth.
Compare STVN with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Stevanato Group SpA (STVN) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Stevanato Group SpA is a strong growth company balancing expansion with improving profitability. Revenue reached 1.2B with 480% growth year-over-year. Profit margins of 11.8% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 480% YoY, reaching 1.2B. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
ROE of 967.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can Stevanato Group SpA push profit margins above 15% as the business scales?
Growth sustainability: can Stevanato Group SpA maintain 480%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Stevanato Group SpA.
Bottom Line
Stevanato Group SpA offers an attractive blend of growth (480% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:05 AM
About Stevanato Group SpA(STVN)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.